10-Q: Glucotrack Advances CBGM, Faces Going Concern & Control Issues

Glucotrack, Inc. reported progress in its implantable glucose monitor clinical trials and significant capital raises, but disclosed substantial doubt about its ability to continue as a going concern and identified material weaknesses in internal controls.

Summary

• Completed a first-in-human (FIH) short-term clinical study for its implantable continuous blood glucose monitor (CBGM) in Q1 2025, meeting all primary and secondary endpoints with a Mean Absolute Relative Difference (MARD) of 7.7% and no serious adverse events.
• Obtained regulatory approval for a long-term clinical study outside the United States, with patient enrollment expected to begin in Q3 2025.
• Initiated discussions with the FDA for a pre-investigational device exemption (IDE) submission in Q2 2025, with an IDE submission expected in Q4 2025 for future US trials.
• Raised $10.7 million in net proceeds from equity offerings during the first six months of 2025, significantly increasing cash and cash equivalents to $9.555 million as of June 30, 2025, from $5.617 million at December 31, 2024.
• Reported a net loss of $11.589 million for the six months ended June 30, 2025, compared to $7.416 million for the same period in 2024, primarily due to increased general and administrative expenses and changes in derivative liability fair value.
• Accumulated deficit increased to $144.039 million as of June 30, 2025.
• Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern, as current cash is not expected to fund operations for the next twelve months, estimating a need for approximately $15.0 million.
• Implemented two reverse stock splits in 2025: 1-for-20 in February and 1-for-60 in June, and increased authorized common stock from 100 million to 250 million shares.
• Identified material weaknesses in internal control over financial reporting related to general IT controls, insufficient accounting personnel, and inadequate segregation of duties, though no material misstatements resulted.

Sentiment

Score: 4

Explanation: While there is significant positive progress in clinical development and a substantial capital raise, the explicit 'going concern' warning, increased net loss, and identified material weaknesses in internal controls present considerable financial and operational challenges, tempering overall sentiment.

Positives

• Successful completion of the first-in-human (FIH) clinical study for the Glucotrack CBGM, meeting all primary and secondary endpoints with no serious adverse events.
• Achieved excellent accuracy with a Mean Absolute Relative Difference (MARD) of 7.7% in the FIH study, which compares favorably to commercially available continuous glucose monitoring (CGM) systems.
• Secured regulatory approval for a long-term clinical study outside the United States, with patient enrollment anticipated in Q3 2025.
• Initiated discussions with the FDA for a pre-investigational device exemption (IDE) submission, signaling progress towards US clinical trials.
• Significantly improved liquidity by raising $10.7 million in net proceeds from equity offerings during the first half of 2025, increasing cash and cash equivalents to $9.555 million.
• Reduced derivative financial liabilities from $17.421 million at December 31, 2024, to $5 thousand at June 30, 2025, largely due to cashless warrant exchanges.
• Shifted from a total stockholders' deficit of $(13.000) million at December 31, 2024, to positive equity of $6.880 million at June 30, 2025.
• Research and development expenses decreased to $5.021 million for the six months ended June 30, 2025, from $5.737 million in the prior-year period.

Negatives

• Reported a significant increase in net loss to $11.589 million for the six months ended June 30, 2025, compared to $7.416 million for the same period in 2024.
• Accumulated deficit grew to $144.039 million as of June 30, 2025, indicating continued unprofitability since inception.
• Experienced increased cash used in operating activities, rising to $6.683 million for the six months ended June 30, 2025, from $4.849 million in the prior-year period.
• General and administrative expenses increased substantially to $2.963 million for the six months ended June 30, 2025, from $1.535 million in the prior-year period, driven by higher legal, professional fees, and personnel costs.
• Marketing expenses increased to $310 thousand for the six months ended June 30, 2025, from $170 thousand in the prior-year period.
• Incurred a $95 thousand loss on the repurchase of Series A Warrants.
• The company's current cash and cash equivalents are not expected to be sufficient to fund operating cash flow needs for at least the next twelve months, requiring approximately $15.0 million in additional capital.

Risks

• Substantial doubt exists about the Company's ability to continue as a going concern due to recurring losses, negative cash flow from operations, and insufficient current cash to fund operations for the next twelve months.
• Dependence on external sources for financing operations, with no assurance that necessary financing will be available on acceptable terms or at all.
• Inability to raise capital could force delays, reductions, or elimination of clinical trials or other operations, adversely affecting operational goals.
• Identified material weaknesses in internal control over financial reporting, specifically in general IT controls, lack of sufficient accounting personnel, and inadequate segregation of duties.
• The company has not yet commercialized its Glucotrack CBGM, and further development and commercialization efforts are expected to require substantial additional expenditure.
• Future capital requirements and the adequacy of available funds depend on many factors, including those described in the Risk Factors section of the Annual Report on Form 10-K for the year ended December 31, 2024.
• Contingent liability to the Israeli Innovation Authority (IIA) for royalties (3-5%) on future sales arising from the Development Plan, up to $93 thousand plus LIBOR interest, with no expiration date.

Future Outlook

The company plans to initiate a long-term clinical study for its Glucotrack CBGM outside the United States in Q3 2025, following regulatory approval in Q2 2025. Discussions with the FDA for a pre-investigational device exemption (IDE) submission have begun, with the IDE submission expected in Q4 2025 to pave the way for future long-term human clinical trials in the United States. The company anticipates increased research and development expenses in 2025 and beyond due to expanding clinical trial activities and personnel hiring. Management expects to finance operations through additional equity or debt securities, license agreements, or collaborative arrangements, but there is no assurance of securing such financing.

Management Comments

• "We believe that implant accuracy and longevity is key to the success for long term use."
• "Our technology, if successful, has the potential to be a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration."
• "Management has considered the significance of such conditions in relation to the Company's ability to meet its current obligations and to achieve its business targets and determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern."
• "We expect research and development expenses to increase in 2025 and beyond, primarily due to expanding clinical trial activities, hiring additional personnel, as well the development of the Glucotrack CBGM."
• "We have raised and believe we will continue to be able to raise additional capital through debt financing, private or public equity financings, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing."

Industry Context

Glucotrack operates in the highly competitive and rapidly evolving diabetes management market, specifically focusing on continuous glucose monitoring (CGM). Its implantable CBGM aims to differentiate itself by offering a long-term (3-year sensor life), fully implantable solution that measures glucose directly from blood, eliminating the lag time associated with traditional interstitial fluid-based CGMs. This approach addresses a key pain point for diabetes patients by removing the need for on-body wearable components and minimizing calibration, potentially offering a more convenient and less burdensome solution compared to existing market leaders like Dexcom and Abbott. The positive first-in-human study results, particularly the MARD of 7.7%, position Glucotrack favorably against current commercial systems, suggesting a strong competitive offering if successfully commercialized.

Comparison to Industry Standards

• The Glucotrack CBGM's Mean Absolute Relative Difference (MARD) of 7.7% from its first-in-human study demonstrates very high accuracy.
• This MARD value compares favorably to commercially available continuous glucose monitoring (CGM) systems, which typically report MARD values ranging from 8-10% (e.g., Dexcom G6/G7, Abbott FreeStyle Libre).
• The system's design for a three-year sensor life with no on-body wearable component and minimal calibration requirements offers a potential advantage in convenience and patient adherence over existing systems that require frequent sensor changes (e.g., every 10-14 days for Dexcom and Abbott products).
• The direct blood glucose measurement eliminates the lag time associated with interstitial fluid glucose monitors, a common limitation of current commercial CGM devices.

Management Changes

Corporate Governance

Legal Proceedings

• No pending claims, charges, or litigation were expected to have a material adverse impact on financial position, results of operations, or cash flows as of June 30, 2025.

Related Party Transactions

• Intellectual Property Purchase Agreement with Paul Goode (CEO) on October 7, 2022, for which he receives up to 10,000 shares of Common Stock based on specified performance milestones, plus potential True-Up Shares.
• Paul Goode (CEO) achieved the first, second, and third performance milestones, resulting in commitments to issue 17, 25, and 42 restricted shares, respectively, with associated stock-based compensation expenses.
• Note and warrant purchase agreements on June 27, 2024, with certain officers, directors, and existing investors for unsecured promissory notes and warrants.

Stakeholder Impact

• Shareholders: Significant dilution from recent equity offerings and warrant exchanges, coupled with reverse stock splits, has altered per-share metrics. The "going concern" warning poses a substantial risk to investment value. Positive clinical trial results offer potential long-term value if commercialization is successful.
• Employees: Continued operational losses and the need for further financing may create uncertainty regarding job security and future growth opportunities, though the company is hiring additional accounting personnel.
• Customers (future): The successful first-in-human study and planned long-term trials indicate progress towards a potentially innovative and convenient diabetes management solution.
• Creditors: The "going concern" warning and dependence on future financing may raise concerns about the company's ability to meet its obligations, although current cash levels have improved.
• Regulatory Bodies (FDA, IIA): Ongoing engagement with the FDA for IDE submission and existing royalty obligations to the Israeli Innovation Authority highlight regulatory compliance and financial commitments.

Next Steps

• Begin patient enrollment for a long-term clinical study outside the United States in Q3 2025.
• File an Investigational Device Exemption (IDE) submission to the FDA during Q4 2025 for future long-term human clinical trials in the United States.
• Implement proper IT system access controls and backup of IT architecture to remediate material weaknesses in internal controls.
• Outsource certain accounting functions and hire additional accounting personnel to address internal control deficiencies.
• Seek additional capital through debt financing, private or public equity financings, license agreements, collaborative agreements, or other arrangements to fund future operations.
• Continue to evolve sensor chemistry and develop the Glucotrack CBGM.

Key Dates

Recommendation

Despite positive clinical trial progress for the Glucotrack CBGM and a significant capital raise, the company explicitly states 'substantial doubt about its ability to continue as a going concern.' It has a history of recurring losses, negative cash flow from operations, and projects needing an additional $15.0 million within the next 12 months, with no assurance of securing this financing. Furthermore, material weaknesses in internal controls over financial reporting indicate significant operational risks. While the MARD of 7.7% is promising, the severe financial instability and governance issues outweigh the clinical advancements, making the stock a high-risk investment with significant downside potential. A seasoned investor would likely view the going concern warning and control deficiencies as critical red flags, suggesting an exit or avoidance of the stock.

Keywords

Glucotrack, GCTK, Continuous Glucose Monitor, CBGM, Diabetes, Medical Device, SEC Filing, 10-Q, Clinical Trials, FDA Approval, Financial Results, Going Concern, Equity Offering, Reverse Stock Split, Biotechnology, Healthcare